Table 1 Patients´ demographic and clinical characteristics
From: Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
Characteristic | Value (n = 181) |
|---|---|
Median age (range), years | 71.4 (62.2–79.0) |
Gender, n (%) | |
Male | 69 (38.1) |
Female | 112 (61.9) |
Race, n (%) | |
Caucasian | 178 (98.3) |
Asian | 3 (1.7) |
Smoking history, n (%) | |
Former smoker | 53 (30.3) |
Current smoker | 26 (14.9) |
Never smoker | 96 (54.9) |
ECOG PS at diagnosis of advanced disease, n (%) | |
0 | 46 (27.7) |
1 | 87 (52.4) |
2 | 26 (15.7) |
3 | 7 (8.1) |
Tumor histology, n (%) | |
Adenocarcinoma | 161 (89.0) |
Squamous cell carcinoma | 9 (5.0) |
Large cell carcinoma | 5 (2.8) |
Adenosquamous cell carcinoma | 2 (1.1) |
Carcinoma NOS | 4 (2.2) |
Clinical stage at diagnosis, n (%) | |
IIIA | 8 (4.4) |
IIIB | 7 (3.9) |
IV | 159 (87.8) |
Othera | 7 (4) |
Median number of metastatic sites (range) | 2.0 (1.0–3.0) |
Metastases location, n (%)b | |
Lung | 80 (45.7) |
Bone | 75 (42.9) |
Pleura | 50 (28.6) |
Lymph nodes | 45 (25.7) |
Pleural effusion | 30 (17.1) |
CNS | 25 (14.3) |
Liver | 25 (14.3) |